acute myeloid leukemia
Conditions
Interventions
VEN Sensitivity Group:An AML cell line with CLL-1 knockout was constructed and co-cultured with different concentrations of VEN. AML patients with refractory relapse and CLL-1 expression bigroups were
Mechanism group of VEN resistance:AML cell lines and CLL-1 knockout AML cell lines were selected and co-cultured with appropriate concentrations of VEN
AML patients with refractory relapse and CLL-1 expression bigroups were sorted by flow cytometry or immunomagnetic beads, and co-cultured with appropriate concentrations of VEN
AML cell lines and CLL-1 knockout AML cell lines with ROR1-NF-?B pathway inhibitors added
For AML patients with refractory relapse and CLL-1 expression bigroups, ROR1-NF-?B pathway inhibitors were added
Sponsors
Tianjin First Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1)Refractory and/or relapsed AML patients of two populations of cells with CLL-1 negativity and positivity; 2) Male or female patients, aged 18-65 years (including cut-off value); 3) Adequate organ function reserve: a) alanine aminotransferase/aspartate aminotransferase = 60 mL/min; c) Serum total bilirubin =50% by echocardiography, and there was no large pericardial effusion, and no clinically intentional ECG abnormality; e) Basal oxygen saturation >92% in indoor natural air environment; 4)ECOG<=2.
Exclusion criteria
Exclusion criteria: 1) Patients who are positive of anti-HIV antibody ; 2) Patients with a history of the following hereditary diseases: such as Fanconi anemia, Schuet-Day syndrome, Kostmann's syndrome, or any other known bone marrow failure syndrome; 3) Patients with a history of central nervous system disease such as seizure disease, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving the CNS; 4) Patients with a history of severe allergies or allergies; 5) Patients with a history of autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) that causes terminal organ damage or requires systemic immunosuppressive/systemic disease-modifying drugs within the past 2 years; 6) Patients with a history of interstitial lung disease (such as pneumonia, pulmonary fibrosis); 7) Patients who have received gene therapy or other CAR-T product treatment; 8) lactating females; 9) Those who have poor compliance due to physiological, family, social, geographical and other factors, and cannot cooperate with the research protocol; 10) Patients with a history of other malignant tumors; 11) Patients who have a severe mental disorder; 12) Patients who have grade II-IV aGVHD or extensive cGVHD; 13) Patients who have grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent cardiac disease within one year prior to enrollment; 14) Patients who have any indwelling catheter or drain (such as percutaneous nephrostomy tube, indwelling urinary catheter, bile drain, or pleura/peritoneal/pericardial catheter), and the use of a dedicated central venous catheter is permitted; 15) Patients who have active hepatitis B or hepatitis C; 16) Any other situation that the investigator considers inappropriate for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity related to VEN;Mechanisms of resistance related to VEN; | — |
Countries
China
Contacts
Public ContactHe Xiaoyuan
Tianjin First Central Hospital
Outcome results
None listed